NCT00380783终止2 期
Safety and Efficacy of AGN 203818 for Pain Associated With Painful Bladder Syndrome/Interstitial Cystitis
适应症
相关药物
试验速览
- 阶段
- 2 期
- 状态
- 终止
- 发起方
- Allergan
- 入组人数
- 2
- 试验地点
- 1
- 主要终点
- Reduction in daily pain scores
研究概览
简要总结
This study will explore the safety and effectiveness of different doses of AGN 203818 in treating the pain associated with painful bladder syndrome/interstitial cystitis
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Double
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- Female
- 接受健康志愿者
- 否
入选标准
- •Diagnosis of painful bladder syndrome/interstitial cystitis
- •Moderate or severe bladder pain
排除标准
- •Any other uncontrolled disease
- •Pregnant or nursing females
结局指标
主要结局
Reduction in daily pain scores
次要结局
未报告次要终点
研究者
研究点 (1)
Loading locations...
相似试验
终止
2 期
Safety and Efficacy of AGN 203818 for Pain Associated With Fibromyalgia SyndromeFibromyalgiaNCT00445705Allergan211
已完成
2 期
Safety and Efficacy of AGN 203818 in Patients With Painful Diabetic Peripheral NeuropathyDiabetic Neuropathy, PainfulNCT00381719Allergan330
终止
2 期
Safety and Efficacy of Oral AGN 203818 for the Relief of Irritable Bowel Syndrome PainIrritable Bowel SyndromeNCT00441766Allergan213
终止
2 期
A Safety and Efficacy Study of AGN-214868 in Patients With Postherpetic NeuralgiaNeuralgia, PostherpeticNCT01678924Allergan280
已完成
2 期
A Study of the Safety and Efficacy of AGN-214868 in Patients With Postherpetic NeuralgiaNeuralgia, PostherpeticNCT01129531Allergan294